+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Master Protocol study focusing on the safety and tolerability of multiple amyloid-targeting drugs in both healthy adults and individuals diagnosed with Alzheimers disease AD. This study aims to evaluate if these drugs can remove amyloid plaque, clumps of protein in the brain linked to AD. Participants will enroll in one of two substudies, either A1D-MC-AT01 or the upcoming A1D-MC-AT02, to assess these treatments. The study involves administering the drug LY4405094 or a placebo either intravenously IV or subcutaneously SC to healthy volunteers and AD participants. Participants with AD will also undergo amyloid positron emission tomography PET scans using Florbetapir F18 or Florbetaben F18 injected intravenously to help monitor amyloid plaque in the brain. The study uses a randomized, double-blind design and includes several substudies depending on participant health status. Participants will be closely monitored throughout the study period, which lasts up to 160 days from baseline. Evaluations include medical exams, electrocardiograms ECGs, cognitive assessments such as the Mini-Mental State Exam MMSE, and brain imaging with PET scans and magnetic resonance imaging MRI. Study partners will assist participants with Alzheimers disease by providing support and consent. Researchers will track the number of participants assigned to each substudy and assess safety and tolerability during the trial.

Age: 18Years - 85YearsAll GendersPhase 1
18 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a one-time intravitreal injection of SAR446597 in people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This Phase 12, two-part, multicenter study aims to understand how the treatment works and its potential benefits over approximately two years, followed by an additional three-year extended follow-up period. Participants will receive a single injection of SAR446597 into the eye or a sham injection, depending on the study part and dose group. Multiple dose levels of SAR446597 will be tested in different participant cohorts, with some receiving the active treatment and others receiving a sham as a control. Part I is open-label, while Part II involves randomized dosing and sham control groups. During the study, participants will be monitored for treatment side effects, changes in vision, and the size of GA lesions using visual acuity tests and lesion measurements at baseline, one year, and two years. Safety assessments will continue through the extended follow-up phase. The study also tracks serious and non-serious adverse events up to two years after treatment, with a total study duration of about five years per participant.

Age: 60Years +All GendersPhase 1Phase 2
35 locations
F

Actively Recruiting

Researchers are evaluating how well different doses of the medicine BI 3812465 are tolerated in adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study includes two parts an initial phase testing low, medium, and high doses sequentially, followed by a phase where more participants receive these doses in a randomized way to assess safety and tolerability. Participants receive BI 3812465 as injections into the back of the eye, with a total of three injections given during the study. In Part 1, a small group receives increasing doses starting from low, and in Part 2, a larger group is randomized to receive one of the three dose levels. The treatment period involves these injections, and dosing only advances if lower doses are tolerated. Participants stay in the study for up to 7 months, attending 19 visits to the study site or, when possible, having visits at their home. During these visits, doctors check the severity of the eye condition and monitor for any health problems related to the medicine. The study measures dose limiting events, ocular adverse events, and other safety outcomes throughout the treatment and follow-up period.

Age: 18Years +All GendersPhase 1Phase 2
29 locations
P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating LY4405094, a drug being studied for safety and how it enters the bloodstream, in both healthy participants and those with Alzheimers Disease. The study aims to understand how much and how quickly LY4405094 reaches the bloodstream and brain fluid, while also assessing levels of a specific Alzheimers-related protein in the brain. This is a Phase 1 trial that includes a placebo comparison and uses both intravenous IV and subcutaneous SC administration methods. Participants are assigned randomly to receive either LY4405094 or a placebo, given by IV or SC in healthy volunteers and by IV in participants with Alzheimers Disease. The study includes a single-ascending dose group and a multiple-ascending dose group. Those with Alzheimers will also undergo amyloid positron emission tomography PET scans using Florbetapir F 18 or Florbetaben F 18 to assess amyloid plaque levels. Study stays include a 4-day clinical research unit visit for healthy volunteers and a 3-day stay for Alzheimers participants. During the study, researchers monitor participants for serious adverse events related to the study drug over up to 25 weeks. They also measure drug concentration levels in blood and cerebrospinal fluid, and track amyloid plaque changes using PET scans. Participants will undergo clinical stays, blood tests, scans, and safety monitoring throughout the study period, which lasts up to 13 weeks for healthy volunteers and 25 weeks for those with Alzheimers Disease.

Age: 18Years - 85YearsAll GendersPhase 1
18 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
157 locations
E

Actively Recruiting

Alzheimers disease is a progressive and irreversible brain disorder that commonly causes dementia in older adults. It begins with mild memory problems such as misplacing items or forgetting events and can worsen to confusion, agitation, and loss of independence. This research aims to test the safety, effects, and how the body processes ABBV-1758, an investigational drug being studied for Alzheimers disease in a multi-stage clinical trial. Participants receive ABBV-1758 or a placebo through intravenous or subcutaneous injections once every four weeks for 24 weeks. The study includes three stages Stage A with multiple dose levels using a 41 randomization, Stage B expanding dosing cohorts, and Stage C enrolling Japanese and Chinese participants with the same randomization. After treatment, participants are followed for 12 weeks and may join a blinded 12-month extension depending on amyloid PET scan results. During the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor safety and effects. Researchers measure outcomes like adverse events, lab test changes, brain amyloid levels, and drug concentration in the blood over approximately 40 weeks. The total participation time includes treatment, follow-up, and possible extension periods.

Age: 50Years - 90YearsAll GendersPhase 1Phase 2
13 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.

Age: 60Years - 85YearsAll GendersPhase 3
119 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations

1-10 of 30

1